Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson’s disease
Objective: To evaluate expression of brain metabotropic glutamatergic receptor 5 and the relationship with clinical measures in Parkinson’s disease patients. Background: Metabotropic glutamate receptor 5…Amyloid PET and cognition in Parkinson’s disease
Objective: To investigate the relationship between cerebral amyloid accumulation and cognition in Parkinson’s disease (PD). Background: The neuropathology underlying the development of dementia in Parkinson’s…Clinical and imaging progression in the PARS cohort: Results from 6 years of observation
Objective: The goal of the Parkinson Associated Risk Syndrome (PARS) study is to explore the clinical and biomarker trajectory of individuals in the pre-motor phase…Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study
Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder
Objective: Study the relationship between RBD and other symptoms of PD. Background: Rapid eye movement sleep behavior disorder (RBD) and Parkinson’s disease (PD) are two…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.